Clinical Trial Update: First-line Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma With Dual Immunotherapy Combined With Chemotherapy [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating first-line dual immunotherapy plus chemotherapy for gastric or gastroesophageal junction adenocarcinoma; the study is not yet recruit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Cancer

Snippet

Sponsor: The First Affiliated Hospital with Nanjing Medical University | Conditions: Gastric or Gastroesophageal Junction Adenocarcinoma | Phase 2 | Status: NOT_YET_RECRUITING